Gapping up
In reaction to strong earnings/guidance: SYNC +8.4%, MUX +5.3%, CSX +3.5%, ASML +3.2%, BAC +2.6%, SN +2.4%, PPHM +2.2%, AEHR +1.9%, (also announced that Gary Larson VP of Finance/CFO plans to retire effective September 8; intends to name Corporate Controller Ken Spink to serve as interim CFO), SAR +1.7%, ADTN +1.2%, PNC +0.5%
M&A news: RCPT +10.5% (to be acquired by Celgene (CELG) for $232/share in cash, or ~$7.2 bln), CELG +7%
Select financial related names showing strength: GS +1.1%, C +1%, MS +0.8%.
Select bio/pharma stocks trading higher: PTCT +12.5% (also, upgraded to Overweight from Neutral at JP Morgan), ARNA +4%, ICPT +2.7%, ZIOP +2.4%, GILD +1.4%, NVO +0.8%
Other news: PETX +7.3% ( announces positive results from its pivotal field effectiveness study of AT-003 for treating post-surgical pain in dogs), MUX +5.3% (reports quarterly production at its El Gallo Mine of 17,325 gold equivalent ounces, above guidance for the quarter), REX +3.7% ( to replace SYNA in the S&P SmallCap 600), SYT +3.5% (Paulson & Co building a stake in the company to back takeover attempt by Monsanto (MON), according to Bloomberg Report), NBG +3.5% (cont vol surrounding Greece Parliament vote today), OCAT +2.5% (receives US patent for its retinal pigment epithelium transplant technology for macular degeneration), FNBC +2.2% (to replace RTI in the S&P SmallCAp 600), SIXD +2.1% (provides business updates),NSC +1.8% (following CSX earnings), FIT +1.8% (cont vol post IPO), GPRO +1.7% (still checking), EYES +1.6% (announces expansion of Argus II availability in Europe), AMD +1% (ASML peer)
Analyst comments: CLSN +12.9% (initiated with a Buy at Maxim Group; tgt $12), GES +6.1% (upgraded to Market Perform from Underperform at Telsey Advisory Group), LNKD +2.6% (upgraded to Overweight from Equal Weight at Barclays), QRVO +2.4% (initiated with a Buy at Mizuho), FCAU +1.6% (initiated with a Outperform at Credit Suisse), PNRA +1.4% (upgraded to Overweight from Underweight at Piper Jaffray
)
In reaction to strong earnings/guidance: SYNC +8.4%, MUX +5.3%, CSX +3.5%, ASML +3.2%, BAC +2.6%, SN +2.4%, PPHM +2.2%, AEHR +1.9%, (also announced that Gary Larson VP of Finance/CFO plans to retire effective September 8; intends to name Corporate Controller Ken Spink to serve as interim CFO), SAR +1.7%, ADTN +1.2%, PNC +0.5%
M&A news: RCPT +10.5% (to be acquired by Celgene (CELG) for $232/share in cash, or ~$7.2 bln), CELG +7%
Select financial related names showing strength: GS +1.1%, C +1%, MS +0.8%.
Select bio/pharma stocks trading higher: PTCT +12.5% (also, upgraded to Overweight from Neutral at JP Morgan), ARNA +4%, ICPT +2.7%, ZIOP +2.4%, GILD +1.4%, NVO +0.8%
Other news: PETX +7.3% ( announces positive results from its pivotal field effectiveness study of AT-003 for treating post-surgical pain in dogs), MUX +5.3% (reports quarterly production at its El Gallo Mine of 17,325 gold equivalent ounces, above guidance for the quarter), REX +3.7% ( to replace SYNA in the S&P SmallCap 600), SYT +3.5% (Paulson & Co building a stake in the company to back takeover attempt by Monsanto (MON), according to Bloomberg Report), NBG +3.5% (cont vol surrounding Greece Parliament vote today), OCAT +2.5% (receives US patent for its retinal pigment epithelium transplant technology for macular degeneration), FNBC +2.2% (to replace RTI in the S&P SmallCAp 600), SIXD +2.1% (provides business updates),NSC +1.8% (following CSX earnings), FIT +1.8% (cont vol post IPO), GPRO +1.7% (still checking), EYES +1.6% (announces expansion of Argus II availability in Europe), AMD +1% (ASML peer)
Analyst comments: CLSN +12.9% (initiated with a Buy at Maxim Group; tgt $12), GES +6.1% (upgraded to Market Perform from Underperform at Telsey Advisory Group), LNKD +2.6% (upgraded to Overweight from Equal Weight at Barclays), QRVO +2.4% (initiated with a Buy at Mizuho), FCAU +1.6% (initiated with a Outperform at Credit Suisse), PNRA +1.4% (upgraded to Overweight from Underweight at Piper Jaffray
)